Jointown Pharmaceutical Group Co., Ltd Stock

Equities

600998

CNE100000W45

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-16 pm EDT 5-day change 1st Jan Change
8.52 CNY +2.16% Intraday chart for Jointown Pharmaceutical Group Co., Ltd +7.30% +21.54%
Sales 2023 * 156B 21.5B Sales 2024 * 174B 24.02B Capitalization 32.21B 4.45B
Net income 2023 * 2.41B 334M Net income 2024 * 2.81B 388M EV / Sales 2023 * 0.25 x
Net Debt 2023 * 7.1B 981M Net Debt 2024 * 9.24B 1.28B EV / Sales 2024 * 0.24 x
P/E ratio 2023 *
13.8 x
P/E ratio 2024 *
11.8 x
Employees 30,141
Yield 2023 *
3.56%
Yield 2024 *
3.91%
Free-Float 40.28%
More Fundamentals * Assessed data
Dynamic Chart
Jointown Pharmaceutical Sets Up Joint AI Lab with Peking University's Wuhan Campus MT
Jiuzhoutong Pharmaceutical Investment Co., Ltd. announced that it expects to receive CNY 10.9100689 billion in funding from Jointown Pharmaceutical Group Co., Ltd CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jointown Pharma's Unit Gets Nod for Registration of Acarbose Tablets MT
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing IASO Biotherapeutics announced that it has received funding from Shanghai Chuanghehui Investment Management Co., Ltd., Jointown Pharmaceutical Group Co., Ltd CI
Fujian Fukang Pharmaceutical Co., Ltd. announced that it has received funding from Shaoxing Shangyu Hangzhou Bay Economic Development Zone Holding Group Co., Ltd., Jointown Pharmaceutical Group Co., Ltd CI
Jointown Pharmaceutical Group Co., Ltd announces decision of Regulatory Authority on the transaction CI
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 26, 2022. CI
Jointown Pharmaceutical Group Co., Ltd's Equity Buyback announced on April 26, 2022, has expired with 36,138,098 shares, representing 1.94% for CNY 425.67 million. CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Jointown Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on April 26, 2022. CI
Jointown Pharmaceutical Group Co., Ltd announced that it expects to receive CNY 2.33 billion in funding CI
Jointown Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
More news
1 day+2.16%
1 week+7.30%
Current month+5.71%
1 month+5.71%
3 months+18.66%
6 months+10.79%
Current year+21.54%
More quotes
1 week
8.02
Extreme 8.02
8.62
1 month
7.70
Extreme 7.7
8.62
Current year
6.52
Extreme 6.52
8.95
1 year
6.50
Extreme 6.5
8.95
3 years
5.12
Extreme 5.1198
8.95
5 years
5.12
Extreme 5.1198
9.87
10 years
5.12
Extreme 5.1198
16.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 38 21-09-30
Chairman 42 17-07-31
Chairman 51 14-08-31
Members of the board TitleAgeSince
Founder 71 99-02-28
Director/Board Member 64 08-11-15
Director/Board Member 46 08-10-31
More insiders
Date Price Change Volume
24-04-17 8.52 +2.16% 30,529,100
24-04-16 8.34 -0.12% 31,025,660
24-04-15 8.35 +3.73% 28,793,540
24-04-12 8.05 -0.49% 10,028,310
24-04-11 8.09 +1.89% 14,156,830

End-of-day quote Shanghai S.E., April 16, 2024

More quotes
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Company’s products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.52 CNY
Average target price
10.18 CNY
Spread / Average Target
+19.54%
Consensus
  1. Stock Market
  2. Equities
  3. 600998 Stock